GNG2 and colorectal carcinoma: To search for druggable targets in LNM-positive T1 CRC, we investigated 84 proteins that were overrepresented in LNM-positive patients and identified 19 US Food and Drug Administration (FDA)-approved drug targets: F13A1, GBA, GNG2, GUCY1B3, STK3, STK4, VWF, etc. (Figure 2C and Figure 2—source data 2).